Brukinsa (zanubrutinib) — United Healthcare
Small Lymphocytic Lymphoma (SLL)
Initial criteria
- Diagnosis of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Brukinsa therapy
Approval duration
12 months